Results 351 to 360 of about 1,109,482 (395)

Treatment of chronic hepatitis C

Journal of Hepatology, 1991
alpha-Interferon given subcutaneously at doses between 1-3 million units leads to responses in about 50% of patients suffering from chronic hepatitis C. A 24-week treatment is frequently (approx. 50%) followed by relapses reducing the percentage of lasting responders to approx. 20%.
openaire   +2 more sources

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Annals of Internal Medicine, 2004
S. Hadziyannis, H. Sette, T. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, D. Bernstein, M. Rizzetto, S. Zeuzem, P. Pockros, A. Lin, A. Ackrill   +13 more
semanticscholar   +1 more source

Chronic Hepatitis C

Medical Clinics of North America, 2023
Saleh A. Alqahtani, Mark S. Sulkowski
openaire   +1 more source

Chronic Hepatitis C: Early Intervention

Hospital Practice, 1998
Chronic hepatitis C infection is the most common liver disease in the United States; it accounts for up to 12,000 deaths annually and is the most common referral for liver transplantation. Recognition of acute infection is desirable because treatment may prevent chronicity.
openaire   +2 more sources

Natural history of liver fibrosis progression in patients with chronic hepatitis C

The Lancet, 1997
T. Poynard, P. Bedossa, P. Opolon, Metavir Clinivir and Dosvirc groups for the OBSVIRC   +3 more
semanticscholar   +1 more source

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

Nature Genetics, 2009
V. Suppiah, Max Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M. Abate, M. Bassendine, U. Spengler, G. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Müller, M. Bahlo, G. Stewart, D. Booth, J. George   +18 more
semanticscholar   +1 more source

Sampling variability of liver fibrosis in chronic hepatitis C

Hepatology, 2003
P. Bedossa, D. Dargère, V. Paradis
semanticscholar   +1 more source

Onconephrology: The intersections between the kidney and cancer

Ca-A Cancer Journal for Clinicians, 2021
, Kenar D Jhaveri, Mark A Perazella
exaly  

[Chronic hepatitis C].

Nihon rinsho. Japanese journal of clinical medicine, 2002
Eleven years have elapsed since the hepatitis type C was first reported and treatment with interferon alone has resulted in about 30% recovery in man. In the case of heavy infection by HCV genotype 1b, 2a, interferon treatment has not been wholly satisfactory and treatment with long term combination of interferon and ribavirin appears to be most ...
openaire   +1 more source

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

Nature Genetics, 2009
Yasuhito Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, S. Hige, Yoshito Ito, E. Mita, E. Tanaka, S. Mochida, Y. Murawaki, M. Honda, A. Sakai, Y. Hiasa, S. Nishiguchi, A. Koike, I. Sakaida, M. Imamura, Kiyoaki Ito, K. Yano, N. Masaki, F. Sugauchi, N. Izumi, K. Tokunaga, M. Mizokami   +28 more
semanticscholar   +1 more source